CDC Entreprises et al. back Biom’Up with €6.8m

CDC invested through the InnoBio fund under the FSI France Investissement programme. Exisitng investors include Merieux Developpement, SHAM, Sofimac Partners, Aquasourca and L'Ameliane, alongside founders and managers Sylvain Picot and Patricia Forest.

The funds will be used to strengthen the sales force targeting the French market as well as Europe and the US. Biom'Up will also finance a phase III clinical trial in Europe and the US for products used in surgery and regenerative medicine.

Company
Created by Sylvain Picot, Patricia Forest and Dr Christian Gagnieu in 2005, Biom'Up was spun out of the Institut National des Sciences Appliquees (INSA) and the Faculte de Pharmacie (Universite Claude Bernard) in Lyon.

The company designs, develops and manufactures reabsorbable medical implants for a range of surgical applications from nerve regeneration to cardio-thoracic surgery. It has also developed proprietary products COVA (a membrane for controlled healing) and MATRI BONE (a bone regeneration matrix).

Biom'Up employs 27 people and is based in Saint-Priest near Lyon.

People
Investors working on the transaction include Thibaut Roulon at CDC, Jerome Feraud at Viveris, Emmanuelle Deponge at OTC, Francois-Regis Ory at L'Ameliane, Stephane Gay at Aquasourca, Paul-Louis Santy at Merieux, Olivier Szymkowiak at SHAM and Cecile Thebault at Sofimac.

Advisers
Equity – Alerion (Legal); Pericles (Legal); Becker & Associes, Camille Lebrette, Philippe Becker (IP due diligence).
Company – MAGS Avocats, Alek Klioua (Legal); Regimbeau, Franck Tetaz, Sylvain Thivillier (IP due diligence); ODICEO, Frederic Gangolphe, Agnes Lamoine (Financial due diligence).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• France
• Healthcare
• France
• CDC Entreprise Innovation
• Sofimac